Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycophenolate mofetil: a unique immunosuppressive agent

K A Hood1, D G Zarembski

  • 1Department of Pharmacy, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|February 1, 1997
PubMed
Summary

Mycophenolate mofetil effectively prevents allograft rejection in kidney transplant patients by inhibiting lymphocyte proliferation. While generally safe, gastrointestinal issues are common, and further research is needed for its broader application.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peloruside A enhances apoptosis in H-ras-transformed cells and is cytotoxic to proliferating T cells.

Apoptosis : an international journal on programmed cell death·2004
Same author

The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C.

Anti-cancer drug design·2002
Same author

Induction of apoptosis by the marine sponge (Mycale) metabolites, mycalamide A and pateamine.

Apoptosis : an international journal on programmed cell death·2001
Same author

Mycalamide D, a new cytotoxic amide from the New Zealand marine sponge Mycale species.

Journal of natural products·2000
Same author

Impact of rifampin on serum amiodarone concentrations in a patient with congenital heart disease.

Pharmacotherapy·1999
Same author

Meta-analysis of the use of low-dose beta-adrenergic blocking therapy in idiopathic or ischemic dilated cardiomyopathy.

The American journal of cardiology·1996

Area of Science:

  • Immunopharmacology
  • Transplantation Medicine
  • Drug Metabolism

Background:

  • Mycophenolate mofetil is an immunosuppressive agent used in solid-organ transplantation.
  • It functions as a prodrug, hydrolyzed to mycophenolic acid, which inhibits purine synthesis.
  • This mechanism leads to antiproliferative effects on T and B lymphocytes, crucial for preventing rejection.

Purpose of the Study:

  • To review the mechanism of action, pharmacokinetics, clinical efficacy, adverse effects, and dosage of mycophenolate mofetil.
  • To assess its role in preventing and treating allograft rejection.
  • To explore its potential in managing other conditions like psoriasis.

Main Methods:

  • Review of existing literature on mycophenolate mofetil.

Related Experiment Videos

  • Analysis of clinical trial data in renal, liver, and heart transplant recipients.
  • Examination of pharmacokinetic and pharmacodynamic properties.

    • Main Results:

    • Mycophenolate mofetil demonstrates efficacy in preventing acute rejection and as rescue therapy in renal transplants.
    • Its role in liver and heart transplantation requires further investigation due to limited data.
    • The drug is effective for long-term psoriasis management, with gastrointestinal issues being the most frequent adverse effects.

    Conclusions:

    • Mycophenolate mofetil is a valuable immunosuppressant, particularly for kidney transplant recipients.
    • While generally well-tolerated, potential links to bone marrow suppression and malignancies warrant consideration.
    • Further studies are necessary to fully elucidate its therapeutic potential and optimal use in various transplant settings.